secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2026-06-09T20:01:28+00:00
Accession:  0001104659-26-071814
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

German antitrust regulator clears Esperion acquisition by ArchiMed
------------------------------------------------------------------

- Bundeskartellamt cleared the merger effective June 2, 2026, as notified June 8.
- Completion still requires HSR waiting period expiration and stockholder approval.
- Special stockholder meeting to vote on merger scheduled for July 8, 2026, at 8:00 a.m. ET.
- Merger announced May 1, 2026; Esperion to become wholly owned by ArchiMed affiliate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000110465926071814/0001104659-26-071814-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000110465926071814/tm2617356d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-071814

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer